Search Results

liabilities, or identify true best-in-class candidates faster Unlock “Drug Binding Kinetics” Now Only in Terry

Terry Kenakin will conduct two consecutive courses in September and October 2024.

Nicole Perry-Hauser, on her selection as a 2024 Discovery Science Emerging Scholar at Vanderbilt University Terry Kenakin. The course covers basic pharmacology in four weekly segments.

It took data, yes—but also a deep partnership with GPCR legend Terry Kenakin to bridge industry credibility

Terry Kenakin's educational initiative this fall!

Terry Kenakin will return for two consecutive courses in September and October 2024.

Terry Kenakin.

Terry Kenakin will lead two brand-new, back-to-back courses tailored for the Dr.

Terry Kenakin.

Terry Kenakin will return for two consecutive courses in September and October 2024.

Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr.

Terry Kenakin, Dr. Oliver Hartley, Dr. Pierre Eftekhari, Dr. Lauren Slosky, Dr. Christel Menet, Dr.

Terry Kenakin, was a resounding success; we have a waitlist for those eager to attend this course, which

Terry Kenakin.

Terry Kenakin.

Terry Kenakin. The course covers basic pharmacology in four weekly segments.

Terry Kenakin. The course covers basic pharmacology in four weekly segments. Only ten spots remain.

Terry Kenakin will return for two consecutive courses in September and October 2024.

Terry Kenakin, have been amazing.

Terry Kenakin. Mark your calendars because registration opens on July 18, 2024!

Terry Kenakin, starts February 8th, 2024. Due to popular demand, we have opened additional spots.

Terry Kenakin will conduct two back-to-back courses this fall.

Terry Kenakin. The course covers basic pharmacology in four weekly segments.

Terry Kenakin will return with two back-to-back classes.

Terry Kenakin. We would like to extend our heartfelt thanks to Dr.

Terry Kenakin.

Terry Kenakin’s Applying Pharmacology to Drug Discovery course.

portfolio of GPCR assays and a unique service that utilizes state-of-the-art tools developed by Professor Terry

Hébert and their colleagues research on 'G Protein-Biased Agonists for Intracellular Angiotensin Receptors

Terence Hébert’s work on Comparative study on human iPSC-derived vs. rat neonatal cardiomyocytes.